Research
More than a decade of work on safer, more precise drug therapy. From research with universities and insurers to software that runs at the point of care.
University Hospital Zurich
2009 to 2013
At the Department of Clinical Pharmacology and Toxicology, we started where drug harm becomes visible: in hospital data. We compared how well different data sources detect adverse drug events, and built a transparent model to rate drug interactions.
Performance of different data sources in identifying adverse drug events in
hospitalized patients
Egbring M, Far E, Knuth A, Roos M, Kirch W, Kullak-Ublick GA. European Journal of
Clinical Pharmacology. 2011;67(9):909-918.
DOI
10.1007/s00228-011-1020-9
· PMID
21394526
Validation of a transparent decision model to rate drug interactions
Far E, Curkovic I, Byrne K, Roos M, Egloff I, Dietrich M, Kirch W, Kullak-Ublick GA,
Egbring M. BMC Pharmacology and Toxicology. 2012;13(1):7.
DOI
10.1186/2050-6511-13-7
· PMID
22950884
Innovation Prize of Swiss Insurances
2014
Our Sanitas TeleHealth project, under the patronage of Otto Bitterli, received the Innovation Prize of Swiss Insurances. It offered personalised telemedical support to patients taking multiple medications, to improve safety, adherence and clinical outcomes.
Helsana Innovation Fund
2014 to 2017
Together with the University of Zurich, ETH Zurich and Helsana, and under the patronage of Prof. Dr. med. Thomas Szucs, we researched medication safety. We built predictive models for drug-drug-gene interactions that set new standards in risk prediction.
Large-scale data analysis identified patients at risk and proved that dangerous interactions can be detected early. It also showed the limit: in daily practice, the case volumes can only be managed with clinical intelligence at the moment of prescribing, inside the workflow of physicians and pharmacists.
Analysis of drug-drug interactions in Swiss claims data using tizanidine and
ciprofloxacin as a prototypical contraindicated combination
Jödicke AM, Curkovic I, Zellweger U, Tomka IT, Neuer T, Kullak-Ublick GA, Roos M,
Egbring M. Annals of Pharmacotherapy. 2018;52(10):983-991.
DOI
10.1177/1060028018775914
· PMID
29749261
Prediction of health care expenditure increase: how does pharmacotherapy contribute?
Jödicke AM, Zellweger U, Tomka IT, Neuer T, Curkovic I, Roos M, Kullak-Ublick GA,
Sargsyan H, Egbring M. BMC Health Services Research. 2019;19(1):953.
DOI
10.1186/s12913-019-4616-x
· PMID
31829224
Medication as a risk factor for hospitalization due to heart failure and shock: a
series of case-crossover studies in Swiss claims data
Jödicke AM, Burden AM, Zellweger U, Tomka IT, Neuer T, Roos M, Kullak-Ublick GA,
Curkovic I, Egbring M. European Journal of Clinical Pharmacology.
2020;76(7):979-989.
DOI
10.1007/s00228-020-02835-x
· PMID
32270213
Lohfert Prize
2017
The Lohfert Prize went to the mobile app developed by the Clinical Pharmacology and Toxicology team at the University Hospital Zurich together with the Swiss Tumor Institute, under the patronage of Prof. Andreas Trojan. It records symptoms and treatment side effects during cancer therapy.
A mobile app to stabilize daily functional activity of breast cancer patients in
collaboration with the physician: a randomized controlled clinical trial
Egbring M, Far E, Roos M, Dietrich M, Brauchbar M, Kullak-Ublick GA, Trojan A.
Journal of Medical Internet Research. 2016;18(9):e238.
DOI
10.2196/jmir.6414
· PMID
27601354
Effect of collaborative review of electronic patient-reported outcomes for shared
reporting in breast cancer patients: descriptive comparative study
Trojan A, Bättig B, Mannhart M, Seifert B, Brauchbar MN, Egbring M. JMIR Cancer.
2021;7(1):e26950.
DOI
10.2196/26950
· PMID
33729162
epha.health
2017 to 2021
Entirely self-funded, we built a digital assistant that combines language models with mechanistic simulations to predict the risk of drug-drug-gene interactions. With epha.health, we reached the top 10 of the Swiss Innovation Challenge 2021, among more than 100 innovations from all sectors.
Our medical services funded this work. That kept us independent and in direct contact with the people who use our reviews every day: physicians and pharmacists.
Clinical consultations
Since 2022
Our research now reaches patients directly. We review complex medication plans, assess drug interactions, give second opinions on drug therapy, and determine when pharmacogenetic testing helps and what its results mean for treatment.
In Switzerland, our consultations are reimbursed by health insurance. Privately insured patients can reach us from anywhere in the world.
A decade of research, applied to one patient at a time.